Clozapine for the treatment of pediatric encephalopathy associated with nonketotic hyperglycinemia.

Rev Psiquiatr Salud Ment (Engl Ed)

CTS-549 Research Group (Psychiatry and Neurosciences), Junta de Andalucía, Granada, Spain; Department of Psychiatry, University of Granada, Granada, Spain; Psychiatry Service, San Cecilio University Hospital, Granada, Spain.

Published: December 2022

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rpsmen.2022.10.001DOI Listing

Publication Analysis

Top Keywords

clozapine treatment
4
treatment pediatric
4
pediatric encephalopathy
4
encephalopathy associated
4
associated nonketotic
4
nonketotic hyperglycinemia
4
clozapine
1
pediatric
1
encephalopathy
1
associated
1

Similar Publications

The negative symptoms of schizophrenia include diminished emotional expression, avolition, alogia, anhedonia, and asociality, and due to their low responsiveness to available treatments, are a primary driver of functional disability in schizophrenia. This narrative review has the aim of providing a comprehensive overview of the current research developments in the treatment of negative symptoms in schizophrenia, and begins by introducing the concepts of primary, secondary, prominent, predominant, and broadly defined negative symptoms. We then compare and contrast commonly used research assessment scales for negative symptoms and review the evidence for the specific utility of widely available off-label and investigational treatments that have been studied for negative symptoms.

View Article and Find Full Text PDF

Importance: Amid escalating mental health challenges among young individuals, intensified by the COVID-19 pandemic, analyzing postpandemic trends is critical.

Objective: To examine mental health care utilization and prescription rates for children, adolescents, and young adults before and after the COVID-19 pandemic.

Design, Setting, And Participants: This population-based time trend study used an interrupted time series analysis to examine mental health care and prescription patterns among the French population 25 years and younger.

View Article and Find Full Text PDF

Background: Clozapine exhibits significant therapeutic efficacy in schizophrenia, especially treatment-resistant schizophrenia. However, clozapine can cause agranulocytosis, a fatal adverse effect, and the aim of this study is to explore this mechanism based on network pharmacology and molecular docking.

Method: Six and two databases were used to identify targets associated with clozapine and agranulocytosis, respectively.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!